Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop

Carla J. Greenbaum, Gerald T. Nepom, Lauren K. Wood-Heickman, Diane K. Wherrett, Linda A. DiMeglio, Kevan C. Herold, Jeffrey P. Krischer

Diabetes 2024;73(11):1780–1790

https://doi.org/10.2337/dbi24-0020

Published: 21 August 2024

View article titled, Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop

Journal Articles

Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes

Esther Latres, Carla J. Greenbaum, Maria L. Oyaski, Colin M. Dayan, Helen M. Colhoun, John M. Lachin, Jay S. Skyler, Michael R. Rickels, Simi T. Ahmed, Sanjoy Dutta, Kevan C. Herold, Marjana Marinac

Diabetes 2024;73(6):823–833

https://doi.org/10.2337/dbi23-0012

Published: 13 February 2024

View article titled, Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes

Journal Articles

A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical Care

Carla J. Greenbaum

Diabetes 2021;70(5):1029–1037

https://doi.org/10.2337/db20-1112

Published: 19 May 2021

View article titled, A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical Care

Journal Articles

Uncovering Pathways to Personalized Therapies in Type 1 Diabetes

Peter S. Linsley, Carla J. Greenbaum, Gerald T. Nepom

Diabetes 2021;70(4):831–841

https://doi.org/10.2337/db20-1185

Published: 16 March 2021

View article titled, Uncovering Pathways to Personalized Therapies in Type 1 Diabetes

Journal Articles

Hybrid Insulin Peptides Are Recognized by Human T Cells in the Context of DRB1*04:01

David Arribas-Layton, Perrin Guyer, Thomas Delong, Mylinh Dang, I-Ting Chow, Cate Speake, Carla J. Greenbaum, William W. Kwok, Rocky L. Baker, Kathryn Haskins, Eddie A. James

Diabetes 2020;69(7):1492–1502

https://doi.org/10.2337/db19-0620

Published: 14 April 2020

View article titled, Hybrid Insulin Peptides Are Recognized by Human T Cells in the Context of DRB1*04:01

Journal Articles

Autoantibodies Directed Toward a Novel IA-2 Variant Protein Enhance Prediction of Type 1 Diabetes

Maria J. Acevedo-Calado, Susan L. Pietropaolo, Michael P. Morran, Santiago Schnell, Andrew D. Vonberg, Charles F. Verge, Roberto Gianani, Dorothy J. Becker, Shuai Huang, Carla J. Greenbaum, Liping Yu, Howard W. Davidson, Aaron W. Michels, Stephen S. Rich, Massimo Pietropaolo

Diabetes 2019;68(9):1819–1829

https://doi.org/10.2337/db18-1351

Published: 14 August 2019

View article titled, Autoantibodies Directed Toward a Novel IA-2 Variant Protein Enhance Prediction of Type 1 Diabetes

Includes: Supplementary data

Journal Articles

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA_1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

Michael J. Haller, S. Alice Long, J. Lori Blanchfield, Desmond A. Schatz, Jay S. Skyler, Jeffrey P. Krischer, Brian N. Bundy, Susan M. Geyer, Megan V. Warnock, Jessica L. Miller, Mark A. Atkinson, Dorothy J. Becker, David A. Baidal, Linda A. DiMeglio, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Kevan C. Herold, Jennifer B. Marks, Antoinette Moran, Henry Rodriguez, William E. Russell, Darrell M. Wilson, Carla J. Greenbaum, Type 1 Diabetes TrialNet ATG-GCSF Study Group, Carla J. Greenbaum, Mark A. Atkinson, David A. Baidal, Manuela Battaglia, Dorothy Becker, Penelope Bingley, Emanuele Bosi, Jane Buckner, Mark Clements, Peter G. Colman, Linda DiMeglio, Carmella Evans-Molina, Stephen E. Gitelman, Robin Goland, Peter Gottlieb, Kevan Herold, Mikael Knip, Jeffrey P. Krischer, Ake Lernmark, Wayne Moore, Antoinette Moran, Andrew Muir, Jerry Palmer, Mark Peakman, Louis Philipson, Philip Raskin, Maria Redondo, Henry Rodriguez, William Russell, Desmond A. Schatz, Jay M. Sosenko, Lisa Spain, John Wentworth, Diane Wherrett, Darrell M. Wilson, William Winter, Anette Ziegler, Mark Anderson, Peter Antinozzi, Richard Insel, Thomas Kay, Jennifer B. Marks, Alberto Pugliese, Bart Roep, Jay S. Skyler, Jorma Toppari, Carla J. Greenbaum, Jeffrey P. Krischer, Ellen Leschek, Lisa Spain, Katarzyna Bourcier, Richard Insel, John Ridge, Jay S. Skyler, Carla J. Greenbaum, Lisa Rafkin, Jay M. Sosenko, Jay S. Skyler, Irene Santiago, Jeffrey P. Krischer, Brian Bundy, Michael Abbondondolo, Timothy Adams, Ilma Asif, Jenna Bjellquist, Matthew Boonstra, Cristina Burroughs, Mario Cleves, David Cuthbertson, Meagan DeSalvatore, Christopher Eberhard, Steve Fiske, Julie Ford, Jennifer Garmeson, Susan Geyer, Brian Hays, Courtney Henderson, Martha Henry, Kathleen Heyman, Belinda Hsiao, Christina Karges, Beata-Gabriela Koziol, Lindsay Lane, Shu Liu, Jennifer Lloyd, Kristin Maddox, Jamie Malloy, Julie Martin, Cameron McNeill, Margaret Moore, Sarah Muller, Thuy Nguyen, Jodie Nunez, Ryan O’Donnell, Melissa Parker, M.J. Pereyra, Amy Roberts, Kelly Sadler, Christine Sullivan, Roy Tamura, Elon Walker-Veras, Megan V. Warnock, Keith Wood, Rebecca Wood, Ping Xu, Vanessa Yanek, Kenneth Young, Darlene Amado, Amanda Kinderman, Ashley Leinbach, Jessica Miller, Nichole Reed, Tina Stavros, Ellen Leschek, Lisa Spain, Emily Blumberg, Sean Aas, Gerald Beck, Rose Gubitosi-Klug, Lori Laffel, Robert Vigersky, Dennis Wallace, David Brillon, Robert Veatch, Brett Loechelt, Lindsey Baden, Peter Gottlieb, Michael Green, Ellen Leschek, Adriana Weinberg, Santica Marcovina, Jerry P. Palmer, Jay Tischfield, Adriana Weinberg, William Winter, Liping Yu, Annie Shultz, Emily Batts, Arielle Pagryzinski, Mary Ramey, Meghan Tobin, Kristin Fitzpatrick, Randy Guerra, Melita Romasco, Christopher Webb, Peter Gottlieb, Maya Barr, Mary Drye, Jordan Lykens, Aaron Michels, Allison Schauwecker, Andrea Steck, Paul Wadwa, Carla J. Greenbaum, Jane Buckner, Wei Hao, Sandra Lord, Marli McCulloch-Olson, Mary Ramey, Elaine Sachter, Jenna Snavely, Meghan Tobin, Corinna Tordillos, Dana VanBuecken, Robin Goland, Analia Alvarez, Magdalena Bogun, Rachelle Gandica, Natasha Leibel, Sarah Pollak, Barney Softness, Kristen Williams, Bryce Nelson, James Amrhein, Lisa Looper, Elaine Moreland, Andrew Smith, Beth Weir, Lori Wise, Linda DiMeglio, Carmella Evans-Molina, Manasa Mantravadi, Maureen Mullen, Vanessa Patrick, Maria Spall, Stephanie Woerner, Darrell M. Wilson, Nora Arrizon-Ruiz, Tandy Aye, Laura Bachrach, Karen Barahona, Trudy Esrey, Laura Nally, Stephen E. Gitelman, Mark Anderson, Glenna Auerback, Jeanne Buchanan, Christine T. Ferrara, Karen Ko, Srinath Sanda, Christine Torok, Rebecca Wesch, Michael J. Haller, Anastasia Albanese-O'Neill, Todd Brusko, Miriam Cintron, Jennifer Hosford, Laura M. Jacobsen, Henry Rohrs, Desmond A. Schatz, Janet Silverstein, Paula Towe, David A. Baidal, Carlos Blaschke, Della Matheson, Janine Sanchez, Natalia Sanders-Branca, Jay S. Skyler, Jay M. Sosenko, Antoinette Moran, Janice Leschyshyn, Jennifer McVean, Brandon Nathan, Brittney Nelson, Beth Pappenfus, Jessica Ruedy, Anne Street, Muna Sunni, Darcy Weingartner, Dorothy Becker, Kelli DeLallo, Ana Diaz, David Groscost, Mary Beth Klein, Ingrid Libman, Karen Riley, Henry Rodriguez, Sureka Bollepalli, Rachel Brownstein, Emily Eyth, Danielle Henson, Michele Laine, Dorothy Shulman, William Russell, Faith Brendle, Anne Brown, Brenna Dixon, Justin Gregory, Dan Moore, James Thomas, Kevan Herold, Laurie Feldman, William Tamborlane

Diabetes 2019;68(6):1267–1276

https://doi.org/10.2337/db19-0057

Published: 09 April 2019

View article titled, Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA<sub>1c</sub>, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

Includes: Supplementary data

Journal Articles

Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes—The TrialNet Experience

Carla J. Greenbaum, Cate Speake, Jeffrey Krischer, Jane Buckner, Peter A. Gottlieb, Desmond A. Schatz, Kevan C. Herold, Mark A. Atkinson

Diabetes 2018;67(7):1216–1225

https://doi.org/10.2337/db18-0065

Published: 16 May 2018

View article titled, Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes—The TrialNet Experience

Journal Articles

Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4⁺ T Cells in Patients With Type 1 Diabetes

Meghan L. Marre, John W. McGinty, I-Ting Chow, Megan E. DeNicola, Noah W. Beck, Sally C. Kent, Alvin C. Powers, Rita Bottino, David M. Harlan, Carla J. Greenbaum, William W. Kwok, Jon D. Piganelli, Eddie A. James

Diabetes 2018;67(7):1356–1368

https://doi.org/10.2337/db17-1166

Published: 13 April 2018

View article titled, Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4<sup>+</sup> T Cells in Patients With Type 1 Diabetes

Includes: Supplementary data

Journal Articles

Molecular Signatures Differentiate Immune States in Type 1 Diabetic Families

Yi-Guang Chen, Susanne M. Cabrera, Shuang Jia, Mary L. Kaldunski, Joanna Kramer, Sami Cheong, Rhonda Geoffrey, Mark F. Roethle, Jeffrey E. Woodliff, Carla J. Greenbaum, Xujing Wang, Martin J. Hessner

Diabetes 2014;63(11):3960–3973

https://doi.org/10.2337/db14-0214

Published: 13 October 2014

View article titled, Molecular Signatures Differentiate Immune States in Type 1 Diabetic Families

Includes: Supplementary data

Journal Articles

Low HERV-K(C4) Copy Number Is Associated With Type 1 Diabetes

Mike J. Mason, Cate Speake, Vivian H. Gersuk, Quynh-Anh Nguyen, Kimberly K. O’Brien, Jared M. Odegard, Jane H. Buckner, Carla J. Greenbaum, Damien Chaussabel, Gerald T. Nepom

Diabetes 2014;63(5):1789–1795

https://doi.org/10.2337/db13-1382

Published: 12 April 2014

View article titled, Low HERV-K(C4) Copy Number Is Associated With Type 1 Diabetes

Includes: Supplementary data

Journal Articles

Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants

Jay M. Sosenko, Jay S. Skyler, Craig A. Beam, Jeffrey P. Krischer, Carla J. Greenbaum, Jeffrey Mahon, Lisa E. Rafkin, Della Matheson, Kevan C. Herold, Jerry P. Palmer, and the Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups

Diabetes 2013;62(12):4179–4183

https://doi.org/10.2337/db13-0656

Published: 16 November 2013

View article titled, Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants

Includes: Supplementary data

Journal Articles

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

Kevan C. Herold, Stephen E. Gitelman, Mario R. Ehlers, Peter A. Gottlieb, Carla J. Greenbaum, William Hagopian, Karen D. Boyle, Lynette Keyes-Elstein, Sudeepta Aggarwal, Deborah Phippard, Peter H. Sayre, James McNamara, Jeffrey A. Bluestone, and the AbATE Study Team

Diabetes 2013;62(11):3766–3774

https://doi.org/10.2337/db13-0345

Published: 18 October 2013

View article titled, Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: <subtitle>Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders</subtitle>

Includes: Supplementary data

Journal Articles

Response to Comment on: Greenbaum et al. Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data. Diabetes 2012;61:2066–2073

Carla J. Greenbaum, Craig A. Beam, on behalf of the Type 1 Diabetes TrialNet Study Group

Diabetes 2013;62(6):e8

https://doi.org/10.2337/db13-0115

Published: 17 May 2013

View article titled, Response to Comment on: Greenbaum et al. Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data. Diabetes 2012;61:2066–2073

Journal Articles

Response to Comment on: Greenbaum et al. Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 Diabetes. Diabetes 2012;61:1323–1330

Carla J. Greenbaum, Desmond A. Schatz, Michael J. Haller, Srinath Sanda

Diabetes 2012;61(12):e19

https://doi.org/10.2337/db12-0914

Published: 15 November 2012

View article titled, Response to Comment on: Greenbaum et al. Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 Diabetes. Diabetes 2012;61:1323–1330

Journal Articles

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function

S. Alice Long, Mary Rieck, Srinath Sanda, Jennifer B. Bollyky, Peter L. Samuels, Robin Goland, Andrew Ahmann, Alex Rabinovitch, Sudeepta Aggarwal, Deborah Phippard, Laurence A. Turka, Mario R. Ehlers, Peter J. Bianchine, Karen D. Boyle, Steven A. Adah, Jeffrey A. Bluestone, Jane H. Buckner, Carla J. Greenbaum

Diabetes 2012;61(9):2340–2348

https://doi.org/10.2337/db12-0049

Published: 17 August 2012

View article titled, Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function

Includes: Supplementary data

Journal Articles

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data

Carla J. Greenbaum, Craig A. Beam, David Boulware, Stephen E. Gitelman, Peter A. Gottlieb, Kevan C. Herold, John M. Lachin, Paula McGee, Jerry P. Palmer, Mark D. Pescovitz, Heidi Krause-Steinrauf, Jay S. Skyler, Jay M. Sosenko, on behalf of the Type 1 Diabetes TrialNet Study Group

Diabetes 2012;61(8):2066–2073

https://doi.org/10.2337/db11-1538

Published: 17 July 2012

View article titled, Fall in C-Peptide During First 2 Years From Diagnosis: <subtitle>Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data</subtitle>

Includes: Supplementary data

Journal Articles

Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 Diabetes

Carla J. Greenbaum, Desmond A. Schatz, Michael J. Haller, Srinath Sanda

Diabetes 2012;61(6):1323–1330

https://doi.org/10.2337/db11-1452

Published: 14 May 2012

View article titled, Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 Diabetes

Journal Articles

Comment on: Atkinson. It's Time to Consider Changing the Rules: The Rationale for Rethinking Control Groups in Clinical Trials Aimed at Reversing Type 1 Diabetes. Diabetes 2011;60:361–363

Srinath Sanda, Carla J. Greenbaum

Diabetes 2011;60(6):e17

https://doi.org/10.2337/db11-0253

Published: 21 May 2011

View article titled, Comment on: Atkinson. It's Time to Consider Changing the Rules: The Rationale for Rethinking Control Groups in Clinical Trials Aimed at Reversing Type 1 Diabetes. Diabetes 2011;60:361–363

Journal Articles

Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1)

Jay M. Sosenko, Jay S. Skyler, Jeffrey P. Krischer, Carla J. Greenbaum, Jeffrey Mahon, Lisa E. Rafkin, David Cuthbertson, Catherine Cowie, Kevan Herold, George Eisenbarth, Jerry P. Palmer, the Diabetes Prevention Trial–Type 1 Study Group

Diabetes 2010;59(10):2386–2389

https://doi.org/10.2337/db10-0534

Published: 03 August 2010

View article titled, Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1)

Includes: Supplementary data

NARROW

Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop

Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes

A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical Care

Uncovering Pathways to Personalized Therapies in Type 1 Diabetes

Hybrid Insulin Peptides Are Recognized by Human T Cells in the Context of DRB1*04:01

Autoantibodies Directed Toward a Novel IA-2 Variant Protein Enhance Prediction of Type 1 Diabetes

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA_1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes—The TrialNet Experience

Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4⁺ T Cells in Patients With Type 1 Diabetes

Molecular Signatures Differentiate Immune States in Type 1 Diabetic Families

Low HERV-K(C4) Copy Number Is Associated With Type 1 Diabetes

Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

Response to Comment on: Greenbaum et al. Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data. Diabetes 2012;61:2066–2073

Response to Comment on: Greenbaum et al. Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 Diabetes. Diabetes 2012;61:1323–1330

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data

Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 Diabetes

Comment on: Atkinson. It's Time to Consider Changing the Rules: The Rationale for Rethinking Control Groups in Clinical Trials Aimed at Reversing Type 1 Diabetes. Diabetes 2011;60:361–363

Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1)

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only